
Results from Eli Lily and Incyte’s Phase III study, COV-BARRIER, evaluating baricitinib in the treatment of hospitalised COVID-19 patients did …

It has come to light that, over a 20 year period, Eli Lily has increased the price of its diabetes …
Novo Nordisk’s diabetes drug Victoza (liraglutide), which was found to cut cardiovascular risks in sufferers of heart disease, has failed …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

